ADAR1 Capital Management LLC Acquires New Position in Keros Therapeutics, Inc. $KROS

Key Points

• ADAR1 Capital Management acquired 246,818 shares of Keros Therapeutics, worth approximately $2.64 million and representing about 1.24% of the company. Institutional investors collectively own 71.56% of KROS.
• Keros reported a quarterly loss of $1.45 per share, missing the $1.34 consensus estimate, while analysts expect a full-year loss of $5.27 per share. Insiders have sold 13,768 shares worth roughly $145,000 over the past three months.
• Analyst sentiment is mixed, with a consensus “Hold” rating and a $20.50 target price; recent targets range from $18 to $20, while some firms maintain sell ratings. KROS opened at $11.68, with a market capitalization of approximately $231.6 million.

ADAR1 Capital Management LLC purchased a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 246,818 shares of the company's stock, valued at approximately $2,641,000. ADAR1 Capital Management LLC owned approximately 1.24% of Keros Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. AQR Capital Management LLC bought a new position in Keros Therapeutics during the first quarter valued at approximately $226,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Keros Therapeutics by 15.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,166 shares of the company's stock worth $227,000 after acquiring an additional 2,982 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Keros Therapeutics by 38.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company's stock valued at $7,547,000 after acquiring an additional 205,022 shares in the last quarter. Creative Planning boosted its position in Keros Therapeutics by 40.2% during the second quarter. Creative Planning now owns 24,226 shares of the company's stock worth $323,000 after purchasing an additional 6,948 shares during the period. Finally, Rhumbline Advisers raised its position in shares of Keros Therapeutics by 16.0% in the second quarter. Rhumbline Advisers now owns 51,815 shares of the company's stock valued at $692,000 after purchasing an additional 7,146 shares during the period. Hedge funds and other institutional investors own 71.56% of the company's stock.

Insider Transactions at Keros Therapeutics

In other news, Director Julius Knowles sold 2,625 shares of the firm's stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.73, for a total value of $28,166.25. Following the transaction, the director owned 10,958 shares of the company's stock, valued at approximately $117,579.34. This trade represents a 19.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Lorena Raquel Lerner sold 3,568 shares of the firm's stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $10.29, for a total value of $36,714.72. Following the completion of the transaction, the insider owned 27,559 shares in the company, valued at $283,582.11. This represents a 11.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 13,768 shares of company stock worth $144,979. 12.60% of the stock is owned by insiders.

Keros Therapeutics Price Performance

Shares of KROS stock opened at $11.68 on Wednesday. The stock's fifty day simple moving average is $10.75 and its 200 day simple moving average is $11.70. Keros Therapeutics, Inc. has a one year low of $9.69 and a one year high of $22.55. The firm has a market cap of $231.61 million, a price-to-earnings ratio of -3.16 and a beta of 0.99.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. On average, research analysts anticipate that Keros Therapeutics, Inc. will post -5.27 earnings per share for the current year.

Wall Street Analyst Weigh In

KROS has been the topic of a number of recent analyst reports. Wells Fargo & Company dropped their price objective on Keros Therapeutics from $20.00 to $18.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 4th. HC Wainwright reiterated a "buy" rating and set a $20.00 price target on shares of Keros Therapeutics in a report on Tuesday, August 4th. Zacks Research cut Keros Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Wednesday, July 29th. Wall Street Zen upgraded shares of Keros Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Monday. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Keros Therapeutics in a research note on Wednesday, August 12th. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $20.50.

About Keros Therapeutics

Keros Therapeutics, Inc NASDAQ: KROS is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company's research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company's lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.

Want to see what other hedge funds are holding KROS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source